A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis - Diabetic Gastroparesis Study 2

Allergan Ltd.0 个研究点目标入组 311 人开始时间: 2022年5月26日最近更新: 2022年5月30日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 311

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Male and female participants aged 18 years or older at screening (Visit 1)
•2. T1DM or T2DM of at least 5 years’ duration, with controlled and stable blood glucose levels (ie, no episodes of diabetic ketoacidosis, Hyperosmolar Hyperglycemic Nonketotic Diabetic Syndrome, or severe hypoglycemia within the 6 months preceding screening [Visit 1])
•3. HbA1c = 11.0% at screening (Visit 1) in participants being treated with oral and/or parenteral medications for T1DM or T2DM with the goal of achieving controlled and stable glucose levels
•4. DG defined as at least a 3-month history prior to screening (Visit 1) of symptoms on an ongoing basis that are suggestive of GP (eg, nausea, abdominal pain, post-prandial fullness, bloating, vomiting, and early satiety)
•5. Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period
•A female participant is eligible to participate if she is not pregnant (has a negative urine pregnancy result prior to randomization), not breastfeeding, and at least one of the following conditions applies:
•a. Not a woman of childbearing potential (WOCBP)
•b. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment
•6. Documentation of absence of an obstructing lesion on upper GI series with contrast or upper endoscopy, performed at some time before the
•Run-in period (Visit 2), but after the appearance of symptoms that led to the diagnosis of DG
•7. At least 2 vomiting episodes during the 2 weeks prior to screening (Visit 1), as ascertained by participant history
•8. Delayed GE confirmed by abnormal GEBT, defined as GE half-time (t½) = 79 minutes at the start of the placebo-controlled Run-in Period (Visit 2). In countries where the GEBT is not available, delayed GE may be confirmed by abnormal scintigraphy result (> 60% retention at 2 hours or > 10% at 4 hours). Refer to the Study Reference Manual
•9. The BMI criterion has been removed.
•10. Able to provide written informed consent (IC) prior to any study procedures and willing and able to comply with study procedures
•Additional inclusion criteria for randomization after the 2-week, placebo Run-in
•11. Compliance with the entry of data into the hand-held electronic device on at least 10 of 14 days during the placebo Run-in Period
•12. Compliance with administration of SC twice daily injections, as evidenced by entries made by the participant using the electronic, hand-held device on at least 10 of 14 days during the placebo Run-in Period
•13. At least one vomiting episode at any time during the placebo Run-in Period, as recorded in the DGSSD, using the electronic hand-held device
•14. The average of the daily DGSSS from the 2-week, placebo Run-in Period must be = 16
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1875
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 625

排除标准

•1. Symptomatic Irritable Bowel Syndrome at Screening (Visit 1)
•2. Small intestinal bacterial overgrowth (SIBO) at Screening (Visit 1)
•3. Participants who are actively experiencing anorexia nervosa, bingeeating, bulimia, or other eating disorder at the time of Screening (Visit 1) are excluded regardless of when diagnosis was established.
•4. History of intestinal malabsorption (including celiac disease even if well-controlled on a gluten-free diet) or pancreatic exocrine insufficiency; also, history of non-celiac gluten sensitivity
•5. History of belching disorders, other nausea and vomiting disorders (eg, chronic nausea and vomiting syndrome, cyclic vomiting syndrome, cannabinoid hyperemesis syndrome), or rumination syndrome
•6. History of chronic obstructive pulmonary disease or other causes of pulmonary
•dysfunction that have resulted in CO2 retention
•7. Gastric or duodenal ulcer within 3 months of Screening (Visit 1)
•8. Evidence of hepatic disease defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 3 x ULN, and/or direct bilirubin = 2 x ULN
•9. History of malignancy in the 3 years prior to Visit 1, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
•10. Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube for feeding or decompression
•11. Use of metoclopramide, domperidone, prucalopride, macrolide
•antibiotics (eg, erythromycin, clarithromycin, azithromycin), 5HT4
•agonists (cisapride, tegaserod, and prucalopride) or other drugs
•considered to be GI pro-motility agents for at least 10 days prior to the
•start of the Run-in Period (Visit 2)
•12. Positive results on the urine drug screen at Screening (Visit 1). The sponsor may permit a participant with a positive urine drug screen (UDS) by immunoassay at Screening to continue in screening while confirmatory testing by a more specific method is carried out on an aliquot of the original urine sample. If the confirmatory test is negative, the initial positive UDS will be considered to have been a false-positive urine drug screen and the participant can continue in screening. Confirmatory testing will be done at the discretion of the sponsor and must be approved by the sponsor prior to analysis. The significance of a positive urine drug screen result for drugs prescribed for the participant (ie, barbiturates, benzodiazepines, amphetamines, but not opioids or cannabinoids) should be assessed by the Investigator as to whether their stable-dose usage is clinically appropriate, and, if so, should not be exclusionary; use of these prescribed drugs on an as-needed basis is not allowed.
•13. Currently taking opioids, or expecting to use opioids during the course of the clinical study.
•14. Treatment with glucagon-like peptide-1(GLP-1) agonist for at least 6 weeks prior to the start of the Run-in Period (Visit 2)
•15. History of pyloric injection of botulinum toxin within 6 months of screening
•16. History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, or bariatric procedure (a history of diagnostic endoscopy is not exclusionary)
•17. Randomization in any previous study in which relamorelin was a treatment
•18. Estimated glomerular filtration rate (eGFR) of < 30 mL/min
•19. Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study
•20. Allergic to, or intolerant of egg, wheat, mi

研究者

发起方

Allergan Ltd.

相似试验

进行中（未招募）

1 期

A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersDiabetic Gastroparesis

EUCTR2017-002177-20-LVAllergan Ltd.2,500

进行中（未招募）

1 期

A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisDiabetic GastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disorders

EUCTR2017-002136-16-ITALLERGAN LIMITED2,500

招募中

Unknown

A human study to evaluate the effect of CKDB001 on Cognitive-enhancing functio

KCT0009298Chong Kun Dang Bio100

Unknown

2 期

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

CTRI/2010/091/001332ovartis Health care Private Limited57

进行中（未招募）

1 期

EUCTR2017-002177-20-GBAllergan Ltd.2,500